Amplifier doses first patients in trial and closes new financing

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Cambrian Bio pipeline company Amplifier Therapeutics kicks off Phase 1B clinical trial and secures new financing from Future Ventures and RA Capital Management.

Amplifier Therapeutics, one of Cambrian Bio‘s pipeline companies, today announced the dosing of the first patient in its Phase 1B clinical trial investigating ATX-304, a peripherally restricted pan-AMPK activator being developed for the treatment of cardiometabolic diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2711

Amplifier Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Amplifier Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule AMP-activated protein kinase (AMPK) activators to address age-related diseases. The company's lead candidate, ATX-304, is a peripherally restricted pan-AMPK activator currently in Phase 1B clinical development for metabolic and cardiometabolic disorders including obesity, type 2 diabetes, and related conditions. By targeting AMPK and mitochondrial function to restore cellular energy balance, Amplifier aims to prevent and treat multiple chronic diseases of aging through metabolic reprogramming.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE